Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Triple peptides for the treatment of obesity Retatrutide, a single peptide linked to a fatty diacid moiety, acts as a triple-agonist targeting three receptors: GIP, GLP-1, and glucagon
Our findings elucidated the regulatory network in GLP-1 to obesity and might provide a novel diagnostic and therapeutic target for obesity
Manik and Singh, 2022)
Distinct development goals In addition, stable long-acting amylin receptor activity Neutral-pH formulation Reduced fibril formation tendency However, large enough to matter in the study weight reduction with favorable side-effect profile For example, potential for combination or combined formulation with other peptide therapies Therefore, Early studies supported continued development
